First Case Report of Cutaneous Leishmaniasis Caused by *Leishmania (Leishmania) infantum* in a Brazilian Patient Treated with Adalimumab

Thaíssa Araújo Aquino1, Sofia Sales Martins1, Ciro Martins Gomes1,2, Jorgeth de Oliveira Carneiro da Motta1,3, Daniel Graziani3, Amanda da Mota Silveira Rodrigues4, Rayane Marques Cardoso5, Beatriz Dolabela de Lima6 and Raimunda Nonata Ribeiro Sampaio1,3*

1Hospital University of Brasilia, University of Brasilia, Brasilia, DF, Brazil
2POs graduate of Medical Sciences, Laboratory of Dermatology, Faculty of Medicine, University of Brasilia, Brasilia, DF, Brazil
3POs graduate of the Faculty of Sciences, University of Brasilia, Brasilia Health, DF, Brazil
4Laboratory of Gene Biology, Department of Cell Biology, Institute of Biological Sciences, University of Brasilia, Brasilia, DF, Brazil

Received date: August 22, 2014, Accepted date: October 14, 2014, Published date: October 21, 2014

Copyright: © 2014 Thaíssa Araújo Aquino et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Corresponding author:* Raimunda Nonata Ribeiro Sampaio, Faculty of Medicine, University of Brasilia, SHIS QI 25 Conj 2, Casa 1, Lago Sul, Brasilia, DF, Brazil, Tel: +55618121 6100; E-mail: raimunda.sampaio@gmail.com

**Abstract**

*Leishmania (Leishmania) infantum* is the main etiologic agent of visceral leishmaniasis in American continent. We report a rare case of cutaneous leishmaniasis caused by viscerotropic specie in a patient with ankylosing spondylitis on treatment with adalimumabe and methotrexate. The patient presented no signs of visceral involvement. PCR-RFLP and genetic sequencing demonstrated *Leishmania (Leishmania) infantum*. The patient was treated with N-methyl-glucamine (20 mgSbV/kg/day) for 20 days. Despite of interruption of treatment due to elevation of transaminases (TGO 48 U/L and TGP 62 U/L) for a week, the lesions healed completely.

**Leishmania* infection in patients who are on anti-TNF alpha treatment has to be remembered as an opportunistic disease associated with immunosuppression caused by biological therapies, especially in endemic countries. We consider that the use of immunosuppressive drugs may lead to atypical cases of cutaneous leishmaniasis even by viscerotropic agents.

**Keywords:** Cutaneous leishmaniasis; Mucocutaneous leishmaniasis; *Leishmania (Leishmania) infantum*; Immunosuppressive agents; Tumor necrosis factor-alpha

**Case Report**

A 38-year-old male patient from Minas Gerais, Brazil, suffering from ankylosing spondylitis and psoriasis who was been treated with methotrexate (15 mg per week) and adalimumab (40 mg every other week) developed three ulcers on his left arm after two years of treatment (Figure 1).

No other symptoms such as fever or weight loss were reported. The physical examination revealed no mucous lesions or hepatosplenomegaly. The blood count, electrolytes, liver and kidney function tests were normal. The leishmanin skin test was positive (19×9 mm) and parasite culture in Novy-Mac Neal-Nicolle (NNN) medium was positive for *Leishmania*. Indirect immunofluorescence test was negative. *Leishmania (Leishmania) infantum* was identified by PCR-RFLP from the patient’s skin biopsy sample, which was confirmed by direct sequencing of the PCR product. HIV serology was negative. Histopathological examination showed lymphohistiocytic infiltrate with granulomas (Figure 2).

The patient was treated with N-methyl-glucamine (20 mgSbV/kg/day) for 20 days with interruption of adalimumab and methotrexate during therapy (Figure 3). Although the treatment was discontinued for a week, due to elevation of transaminases (TGO 48 U/L and TGP 62 U/L) the lesions presented clinical cure after the end of therapy.

**Discussion**

In the Northern region of Brazil more than 90% of the Cutaneous Leishmaniasis (CL) are caused by *Leishmania* (Viannia) guyanensis and in other regions 80% by *Leishmania* (Viannia) braziliensis and 20% by *Leishmania* (Leishmania) amazonensis [1,2]. The patient is from the northern region of the state of Minas Gerais where *Leishmania* (Viannia) braziliensis is the main causative agent of CL and it is also an endemic area of visceral leishmaniasis (VL) caused by *Leishmania (Leishmania) infantum*. In the Americas *Leishmania (Leishmania) infantum* also known as *Leishmania* (Leishmania) chagasi is the most commonly species involved in cases of VL and has been occasionally associated with manifestations of CL. These cases are classified as post-kala-azar dermal leishmaniasis that usually occurs after treatment of VL as non-ulcerated popular lesions all over the skin, and rarely as the first manifestation of VL. To date no Brazilian cases of isolated cutaneous lesions caused by viscerotropic *Leishmania* species had been reported.

The fact that *Leishmania (Leishmania) infantum* may cause isolated CL suggests that immune response is crucial to determine the course of infection [3]. Studies have demonstrated that viscerotropic species in Honduras and the Mediterranean region showed low sensitivity to the action of complement, high infectivity and survival in macrophages when compared to dermatrophic strains [4]. The size of the inoculum and the inoculation route also appear to be important in the clinical spectrum of the disease [4]. High levels of intravenously inoculum were associated with visceralization by *Leishmania* (Leishmania) infantum strains in BALB/c mice genetically susceptible [4].
The use of anti-TNF alpha to treat cutaneous disorders such as psoriasis has become increasingly common. The aim of this strategy is to reduce cutaneous immunologic response and heal inflammatory lesions. This kind of therapy is associated with opportunistic infections especially those where granuloma formation plays an important role in the host defense, such as cutaneous tuberculosis and leishmaniasis [4].

Cases reported in Spain of patients treated with adalimumab who developed CL and studies on the immunopathogenesis of the disease suggest that the formation of granulomas in these patients may be related to the induction of Th17 immune response and activation of Toll-like receptor-9 (TLR9) by Leishmania [5].

Despite the Th1 response is classically associated with protection against Leishmania recent studies showed that the production of cytokines related to Th17 lymphocyte activation also appears to be protective [6-8]. The Th17 cells are CD4+ T lymphocytes that produce pro-inflammatory IL-17 primarily by inducing the expression of several inflammatory mediators, and recruitment of neutrophils [9]. Experimental models have shown that a pro-inflammatory action is related to defence against a variety of infectious diseases [7,10,11]. Dendritic cell sand macrophages are capable of responding to IL-17 stimulation with increased production of IL-12, IFN-gamma and nitric oxide, leading to killing of intracellular pathogens [12].

Several aspects of the initial steps of the immune response after Leishmania infection are unknown. The signaling pathway of Toll-like receptors (TLRs) is one of the first systems of defense against Leishmania [13,14]. After the recognition of specific pathogen associated molecular patterns (PAMPs), TLRs trigger the NF-κB releasing which passes into the nucleus and promotes the transcription and synthesis of pro-inflammatory cytokines [13,14].

Recently, TLR9 has been described in a higher proportion in the granulomas produced by Leishmania (Viannia) braziliensis and it was concluded that Leishmania DNA fragments can bind to TLR9 in macrophages and dendritic cells, activating them and acting, as described in mycobacteria, causing pulmonary granulomatous response in rat models [5]. TLR9 could regulate Th17 activation and increase the secretion of IL-17A promoting the formation and maintenance of granulomas mediated by neutrophils [5].

We described a case of CL without visceral manifestation caused by Leishmania (Leishmania) infantum with formation of granulomas in a patient using anti-TNF alpha and methotrexate, both immunosuppressive drugs. In this case, the absence of visceralization could be explained by the presence of cellular immunity demonstrated by the positivity of leishmanin skin test, the granulomatous infiltrate in the histopathological examination and adequate response to the treatment [15]. Cases of CL worsened or triggered during the use of corticosteroids and immunosuppressive drugs such as methotrexate are frequent, however, in the present case the biological therapy may have been the main factor triggering the disease, since it is clearly associated with an increased risk of infections. We strongly believe that this patient was carrying on an unapparent infection by Leishmania (Leishmania) infantum and that anti-TNF alpha had been the trigger for the clinical manifestation of the disease.

To our knowledge this is the first report of human CL caused by Leishmania (Leishmania) infantum without visceral manifestation in Brazil, with only preceding canine VL-associated CL and atypical cases of CL by viscerotropic species [16].
Conclusion

Leishmania infection in patients treated with anti-TNF alpha has to be remembered as an opportunistic disease associated with biological therapies, especially in endemic countries. The role of anti-TNF alpha to CL by viscerotropic species is unclear.

References